ONE-WAYOngoing theme · still written in the latest filings
Clinical development of HMGB1 peptide (redasemtide) for multiple indications
A development program advancing clinical trials of HMGB1 peptide/redasemtide for multiple indications, including epidermolysis bullosa, ischemic stroke, myocardial infarction and cardiomyopathy. It also includes nonclinical development and out-licensing activities for second-generation candidates.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2019 →Still being written about.
Directionhelps1 helps · 0 hurts · 0 flat